Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date24 Jun 2020 |
Target- |
Mechanism- |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date24 Jun 2020 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date01 Jan 1990 |
The efficacy of Huaiqihuang Granules in children with asymptomatic isolated hematuria
/ CompletedNot Applicable A Real-world Study to Evaluate the Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome
This is a multisite, open-label, prospective and registered study designed to evaluate the efficacy and safety of Huai-Qi-Huang granule in children with primary nephrotic syndrome.
/ Active, not recruitingPhase 4 A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency)
This is a multisite, double-blind, randomized, placebo-controlled, and parallel study designed to evaluate the clinical efficacy and safety of Huaiqihuang granule for treatment to children with chronic primary immune thrombocytopenia (Qi Yin deficiency).
100 Clinical Results associated with Qidong Gaitianli Medicines Co., Ltd.
0 Patents (Medical) associated with Qidong Gaitianli Medicines Co., Ltd.
100 Deals associated with Qidong Gaitianli Medicines Co., Ltd.
100 Translational Medicine associated with Qidong Gaitianli Medicines Co., Ltd.